ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of EUR 36.03 billion. The enterprise value is 35.72 billion.

Market Cap	36.03B
Enterprise Value	35.72B

Important Dates

The last earnings date was Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	May 8, 2025

Share Statistics

Current Share Class	146.41M
Shares Outstanding	n/a
Shares Change (YoY)	-0.14%
Shares Change (QoQ)	-0.12%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.49M

Valuation Ratios

The trailing PE ratio is 30.21 and the forward PE ratio is 26.35.

PE Ratio	30.21
Forward PE	26.35
PS Ratio	8.22
PB Ratio	7.09
P/TBV Ratio	17.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.99, with an EV/FCF ratio of 25.25.

EV / Earnings	29.95
EV / Sales	8.13
EV / EBITDA	21.99
EV / EBIT	24.75
EV / FCF	25.25

Financial Position

The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.14.

Current Ratio	3.44
Quick Ratio	2.16
Debt / Equity	0.14
Debt / EBITDA	0.45
Debt / FCF	0.51
Interest Coverage	2,884.43

Financial Efficiency

Return on equity (ROE) is 25.86% and return on invested capital (ROIC) is 16.80%.

Return on Equity (ROE)	25.86%
Return on Assets (ROA)	14.02%
Return on Invested Capital (ROIC)	16.80%
Return on Capital Employed (ROCE)	23.58%
Revenue Per Employee	413,405
Profits Per Employee	112,520
Employee Count	9,980
Asset Turnover	0.68
Inventory Turnover	2.09

Taxes

In the past 12 months, ResMed has paid 235.73 million in taxes.

Income Tax	235.73M
Effective Tax Rate	16.50%

Stock Price Statistics

The stock price has increased by +22.74% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+22.74%
50-Day Moving Average	224.78
200-Day Moving Average	220.35
Relative Strength Index (RSI)	62.60
Average Volume (20 Days)	25

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.77

Income Statement

In the last 12 months, ResMed had revenue of EUR 4.38 billion and earned 1.19 billion in profits. Earnings per share was 8.10.

Revenue	4.38B
Gross Profit	2.63B
Operating Income	1.44B
Pretax Income	1.43B
Net Income	1.19B
EBITDA	1.58B
EBIT	1.44B
Earnings Per Share (EPS)	8.10

Full Income Statement

Balance Sheet

The company has 1.03 billion in cash and 725.32 million in debt, giving a net cash position of 304.53 million.

Cash & Cash Equivalents	1.03B
Total Debt	725.32M
Net Cash	304.53M
Net Cash Per Share	n/a
Equity (Book Value)	5.08B
Book Value Per Share	34.71
Working Capital	2.12B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.49 billion and capital expenditures -76.52 million, giving a free cash flow of 1.41 billion.

Operating Cash Flow	1.49B
Capital Expenditures	-76.52M
Free Cash Flow	1.41B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.99%, with operating and profit margins of 32.79% and 27.22%.

Gross Margin	59.99%
Operating Margin	32.79%
Pretax Margin	32.60%
Profit Margin	27.22%
EBITDA Margin	36.15%
EBIT Margin	32.79%
FCF Margin	32.29%

Dividends & Yields

This stock pays an annual dividend of 1.95, which amounts to a dividend yield of 0.81%.

Dividend Per Share	1.95
Dividend Yield	0.81%
Dividend Growth (YoY)	9.71%
Years of Dividend Growth	3
Payout Ratio	22.19%
Buyback Yield	0.14%
Shareholder Yield	0.95%
Earnings Yield	3.31%
FCF Yield	3.93%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on August 31, 2010. It was a forward split with a ratio of 2.

Last Split Date	Aug 31, 2010
Split Type	Forward
Split Ratio	2

Scores

ResMed has an Altman Z-Score of 12.06 and a Piotroski F-Score of 7.

Altman Z-Score	12.06
Piotroski F-Score	7